Calliditas Therapeutics (CALTX)

Executive Summary

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on orphan renal and hepatic diseases. Its lead product, TARPEYO (budesonide), is approved for IgA nephropathy (IgAN) in the U.S. and has demonstrated strong commercial uptake. The company is also advancing setanaxib, a first-in-class NOX inhibitor, in fibrotic indications including diabetic kidney disease (DKD) and primary biliary cholangitis (PBC). Recent Phase 2 data for setanaxib in DKD showed promising antifibrotic effects, supporting further development. Calliditas’s strategy leverages its in-house development and commercialization capabilities, with a growing pipeline targeting high-unmet-need orphan indications. The company’s near-term value drivers include label expansion for TARPEYO and clinical milestones for setanaxib.

Upcoming Catalysts (preview)

• Q1 2026Setanaxib Phase 2 DKD topline data70% success
• Q2 2026TARPEYO EU approval decision60% success
• Q4 2026Setanaxib Phase 2 PBC data50% success